Nymox Pharmaceutical Corporation
9900 Cavendish Boulevard
Suite 306
St.-Laurent,
QC H4M 2V2
Canada - Map
Phone: 800-936-9669
Fax: 514-332-2227
Web Site: http://www.nymox.com
| Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices. Its products include NicAlert and TobacAlert tests that use urine or saliva to detect use of and exposure to tobacco products; and AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer's disease. The companys products under development comprises NX-1207, which is in phase III trial for the treatment of enlarged prostate; NXC-4720, an antibacterial agent that is in laboratory trials for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat, and other food and drink products, as well as for the treatment of urinary tract and other bacterial infections in humans; and Statins, a class of commonly prescribed cholesterol lowering drugs to treat, prevent, or reduce the risk of Alzheimers disease. It is also in the preclinical stage of developing therapeutic products for oncological indications; and has various diagnostic markers and technologies, including a patented platform for point-of-care testing. Nymox Pharmaceutical was founded in 1989 and is based in St. Laurent, Canada. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Paul Averback M.D., D.A.B.P., 58
Founder, Chairman, Chief Exec. Officer, Pres and Member of Communications Committee |
N/A
| N/A | Mr. Roy M. Wolvin , 54
Chief Financial Officer, Sec. and Treasurer |
N/A
| N/A | Dr. Celine Dupuis MD,CMSQ,DABP, 50
Chief Clinical Officer |
N/A
| N/A | Mr. Jack Gemmell L.L.B., 57
Chief Information Officer, Gen. Counsel, Director and Member of Communications Committee |
N/A
| N/A | Mr. Brian Doyle B.Sc., M.B.A., 54
Sr. Mang. of Global Sales & Marketing |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
0.02 (0.42%) 
Profile
